Hoppe CC, Inati AC, Brown C, et al. Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor. ASH 59th Annual Meeting & Exhibition, abstract 689.
Etranacogene dezaparvovec bij hemofilie B: effectiviteit en veiligheid na 24 maanden
apr 2024 | Benigne hematologie